Eintrag weiter verarbeiten
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7
Gespeichert in:
| Zeitschriftentitel: | Journal of Cellular and Molecular Medicine |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Journal of Cellular and Molecular Medicine, 23, 2019, 8, S. 5486-5496 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian |
|---|---|
| author |
Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian |
| spellingShingle |
Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian Journal of Cellular and Molecular Medicine CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 Cell Biology Molecular Medicine |
| author_sort |
wang, wei |
| spelling |
Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian 1582-1838 1582-4934 Wiley Cell Biology Molecular Medicine http://dx.doi.org/10.1111/jcmm.14432 <jats:title>Abstract</jats:title><jats:p>Circular RNAs (circRNAs), often dysregulated in a variety of human diseases, participate in the initiation and development of cancers. Recently, circMTO1 (a circRNA derived from <jats:italic>MTO1</jats:italic> gene), identified as a tumor suppressor, has been shown to contribute to the suppression of hepatocellular carcinoma. The present study aimed to explore the clinical significance and roles of circMTO1 in liver fibrosis. Here, we found that serum circMTO1 was significantly down‐regulated in chronic hepatitis B (CHB) patients. Interestingly, serum circMTO1 was negatively correlated with fibrosis stages as well as HAI scores. Receiver operating characteristic curve analysis revealed that serum circMTO1 may serve as a diagnostic biomarker for liver fibrosis in CHB patients. Notably, overexpression of circMTO1 led to the suppression of transforming growth factor‐β1‐induced hepatic stellate cells (HSCs) activation. Bioinformatic analysis and luciferase activity assays indicated that circMTO1 was a target of mircoRNA‐17‐5p (miR‐17‐5p). Data from RNA pull‐down assay further confirmed that circMTO1 interacted with miR‐17‐5p. The inhibitory effects of circMTO1 on HSC activation were suppressed by miR‐17‐5p mimics. Further studies showed that Smad7 was a target of miR‐17‐5p. Moreover, circMTO1‐inhibited HSC activation was also blocked down by loss of Smad7. Taken together, we demonstrate that circMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7, and serum circMTO1 may be a novel promising biomarker of liver fibrosis.</jats:p> CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 Journal of Cellular and Molecular Medicine |
| doi_str_mv |
10.1111/jcmm.14432 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY21tLjE0NDMy |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY21tLjE0NDMy |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
1582-1838 1582-4934 |
| issn_str_mv |
1582-1838 1582-4934 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
wang2019circmto1inhibitsliverfibrosisviaregulationofmir175pandsmad7 |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Cellular and Molecular Medicine |
| source_id |
49 |
| title |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_unstemmed |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_full |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_fullStr |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_full_unstemmed |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_short |
CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_sort |
circmto1 inhibits liver fibrosis via regulation of mir‐17‐5p and smad7 |
| topic |
Cell Biology Molecular Medicine |
| url |
http://dx.doi.org/10.1111/jcmm.14432 |
| publishDate |
2019 |
| physical |
5486-5496 |
| description |
<jats:title>Abstract</jats:title><jats:p>Circular RNAs (circRNAs), often dysregulated in a variety of human diseases, participate in the initiation and development of cancers. Recently, circMTO1 (a circRNA derived from <jats:italic>MTO1</jats:italic> gene), identified as a tumor suppressor, has been shown to contribute to the suppression of hepatocellular carcinoma. The present study aimed to explore the clinical significance and roles of circMTO1 in liver fibrosis. Here, we found that serum circMTO1 was significantly down‐regulated in chronic hepatitis B (CHB) patients. Interestingly, serum circMTO1 was negatively correlated with fibrosis stages as well as HAI scores. Receiver operating characteristic curve analysis revealed that serum circMTO1 may serve as a diagnostic biomarker for liver fibrosis in CHB patients. Notably, overexpression of circMTO1 led to the suppression of transforming growth factor‐β1‐induced hepatic stellate cells (HSCs) activation. Bioinformatic analysis and luciferase activity assays indicated that circMTO1 was a target of mircoRNA‐17‐5p (miR‐17‐5p). Data from RNA pull‐down assay further confirmed that circMTO1 interacted with miR‐17‐5p. The inhibitory effects of circMTO1 on HSC activation were suppressed by miR‐17‐5p mimics. Further studies showed that Smad7 was a target of miR‐17‐5p. Moreover, circMTO1‐inhibited HSC activation was also blocked down by loss of Smad7. Taken together, we demonstrate that circMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7, and serum circMTO1 may be a novel promising biomarker of liver fibrosis.</jats:p> |
| container_issue |
8 |
| container_start_page |
5486 |
| container_title |
Journal of Cellular and Molecular Medicine |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346539592515586 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:41:00.173Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=CircMTO1+inhibits+liver+fibrosis+via+regulation+of+miR%E2%80%9017%E2%80%905p+and+Smad7&rft.date=2019-08-01&genre=article&issn=1582-4934&volume=23&issue=8&spage=5486&epage=5496&pages=5486-5496&jtitle=Journal+of+Cellular+and+Molecular+Medicine&atitle=CircMTO1+inhibits+liver+fibrosis+via+regulation+of+miR%E2%80%9017%E2%80%905p+and+Smad7&aulast=Zheng&aufirst=Jianjian&rft_id=info%3Adoi%2F10.1111%2Fjcmm.14432&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346539592515586 |
| author | Wang, Wei, Dong, Ruiling, Guo, Yong, He, Jianan, Shao, Chaopeng, Yi, Pin, Yu, Fujun, Gu, Dayong, Zheng, Jianjian |
| author_facet | Wang, Wei, Dong, Ruiling, Guo, Yong, He, Jianan, Shao, Chaopeng, Yi, Pin, Yu, Fujun, Gu, Dayong, Zheng, Jianjian, Wang, Wei, Dong, Ruiling, Guo, Yong, He, Jianan, Shao, Chaopeng, Yi, Pin, Yu, Fujun, Gu, Dayong, Zheng, Jianjian |
| author_sort | wang, wei |
| container_issue | 8 |
| container_start_page | 5486 |
| container_title | Journal of Cellular and Molecular Medicine |
| container_volume | 23 |
| description | <jats:title>Abstract</jats:title><jats:p>Circular RNAs (circRNAs), often dysregulated in a variety of human diseases, participate in the initiation and development of cancers. Recently, circMTO1 (a circRNA derived from <jats:italic>MTO1</jats:italic> gene), identified as a tumor suppressor, has been shown to contribute to the suppression of hepatocellular carcinoma. The present study aimed to explore the clinical significance and roles of circMTO1 in liver fibrosis. Here, we found that serum circMTO1 was significantly down‐regulated in chronic hepatitis B (CHB) patients. Interestingly, serum circMTO1 was negatively correlated with fibrosis stages as well as HAI scores. Receiver operating characteristic curve analysis revealed that serum circMTO1 may serve as a diagnostic biomarker for liver fibrosis in CHB patients. Notably, overexpression of circMTO1 led to the suppression of transforming growth factor‐β1‐induced hepatic stellate cells (HSCs) activation. Bioinformatic analysis and luciferase activity assays indicated that circMTO1 was a target of mircoRNA‐17‐5p (miR‐17‐5p). Data from RNA pull‐down assay further confirmed that circMTO1 interacted with miR‐17‐5p. The inhibitory effects of circMTO1 on HSC activation were suppressed by miR‐17‐5p mimics. Further studies showed that Smad7 was a target of miR‐17‐5p. Moreover, circMTO1‐inhibited HSC activation was also blocked down by loss of Smad7. Taken together, we demonstrate that circMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7, and serum circMTO1 may be a novel promising biomarker of liver fibrosis.</jats:p> |
| doi_str_mv | 10.1111/jcmm.14432 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY21tLjE0NDMy |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1582-1838, 1582-4934 |
| issn_str_mv | 1582-1838, 1582-4934 |
| language | English |
| last_indexed | 2024-03-01T17:41:00.173Z |
| match_str | wang2019circmto1inhibitsliverfibrosisviaregulationofmir175pandsmad7 |
| mega_collection | Wiley (CrossRef) |
| physical | 5486-5496 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Cellular and Molecular Medicine |
| source_id | 49 |
| spelling | Wang, Wei Dong, Ruiling Guo, Yong He, Jianan Shao, Chaopeng Yi, Pin Yu, Fujun Gu, Dayong Zheng, Jianjian 1582-1838 1582-4934 Wiley Cell Biology Molecular Medicine http://dx.doi.org/10.1111/jcmm.14432 <jats:title>Abstract</jats:title><jats:p>Circular RNAs (circRNAs), often dysregulated in a variety of human diseases, participate in the initiation and development of cancers. Recently, circMTO1 (a circRNA derived from <jats:italic>MTO1</jats:italic> gene), identified as a tumor suppressor, has been shown to contribute to the suppression of hepatocellular carcinoma. The present study aimed to explore the clinical significance and roles of circMTO1 in liver fibrosis. Here, we found that serum circMTO1 was significantly down‐regulated in chronic hepatitis B (CHB) patients. Interestingly, serum circMTO1 was negatively correlated with fibrosis stages as well as HAI scores. Receiver operating characteristic curve analysis revealed that serum circMTO1 may serve as a diagnostic biomarker for liver fibrosis in CHB patients. Notably, overexpression of circMTO1 led to the suppression of transforming growth factor‐β1‐induced hepatic stellate cells (HSCs) activation. Bioinformatic analysis and luciferase activity assays indicated that circMTO1 was a target of mircoRNA‐17‐5p (miR‐17‐5p). Data from RNA pull‐down assay further confirmed that circMTO1 interacted with miR‐17‐5p. The inhibitory effects of circMTO1 on HSC activation were suppressed by miR‐17‐5p mimics. Further studies showed that Smad7 was a target of miR‐17‐5p. Moreover, circMTO1‐inhibited HSC activation was also blocked down by loss of Smad7. Taken together, we demonstrate that circMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7, and serum circMTO1 may be a novel promising biomarker of liver fibrosis.</jats:p> CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 Journal of Cellular and Molecular Medicine |
| spellingShingle | Wang, Wei, Dong, Ruiling, Guo, Yong, He, Jianan, Shao, Chaopeng, Yi, Pin, Yu, Fujun, Gu, Dayong, Zheng, Jianjian, Journal of Cellular and Molecular Medicine, CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7, Cell Biology, Molecular Medicine |
| title | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_full | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_fullStr | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_full_unstemmed | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_short | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| title_sort | circmto1 inhibits liver fibrosis via regulation of mir‐17‐5p and smad7 |
| title_unstemmed | CircMTO1 inhibits liver fibrosis via regulation of miR‐17‐5p and Smad7 |
| topic | Cell Biology, Molecular Medicine |
| url | http://dx.doi.org/10.1111/jcmm.14432 |